HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Survival Rates for AML Increase From 1980 to 2017
Posted: Jun 30, 2021
Survival Rates for AML Increase From 1980 to 2017 image

According to American AML researchers, between 1980 and 2017 there has been an improvement in survival for AML among all age groups, except for those aged 70 years or older. In a study published in the June issue of Cancer, researchers identified 29,107 patients diagnosed with AML between 1980 and 2017 from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. Patients were classified according to age, and their outcomes were analyzed.

Here are the 5-year survival rates by decade:

For all ages 

Decade 5-Year Survival Rate
1980-1989 9%
1990-1999 15%
2000-2009 22%
2010-2017 28%

 

For ages 15-39

Decade 5-Year Survival Rate
1980-1989 24%
1990-1999 41%
2000-2009 52%
2010-2017 63%
 

For ages ≥70

Decade 5-year Survival Rate
1980-1989 1%
1990-1999 2%
2000-2009 3%
2010-2017 5%
 

Survival has continued to improve, and the best improvement was seen between 2010-2017. As you read these statistics, it’s important to know that there have been major advances in AML treatment since 2017. Ten AML drugs have been FDA-approved since 2017, which has likely improved current survival rates and will continue to improve survival rates in the years to come. 

One of the big reasons for poorer survival rates in the older age groups is historically due to the lack of treatment options available. Intensive chemotherapy and stem cell transplant have often not been options for adults older than 70 due to their harsh side effects. However, of these 10 new FDA-approved drugs, many are options for older adults who are not chemotherapy or stem cell transplant eligible. Three out of these 10 drugs are indicated specifically for adults with AML over the age of 75. These drugs include Ivosidenib for IDH1-mutated AML, Glasdegib and Venetoclax in combination with other medications like Azacitidine. Due to these newer advancements, researchers are optimistic that over the next decade, survival rates for all age groups, especially adults of 70 will improve at a more accelerated rate.

The researchers conclude their study by saying:

“The introduction since 2017 of targeted therapies among older patients and optimizations in supportive care hopefully will continue to improve outcomes in AML, particularly among older patients. We believe we now have many of the therapeutic tools that could improve the cure rates across all AML categories in the next decade”

Looking for an AML Specialist?

If you are looking for an AML specialist who is an expert in using these newer AML therapies, check out our AML Specialist Directory. Doctors who specialize in AML and perform research in AML can provide you with the most effective and appropriate treatments.

 

The author Katie Braswell

about the author
Katie Braswell

Katie joined HealthTree as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Jazz Pharmaceuticals
AbbVie
Amgen
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube